Last reviewed · How we verify
Albumin treatment
Albumin treatment involves the administration of albumin to replace lost albumin in the body.
Albumin treatment involves the administration of albumin to replace lost albumin in the body. Used for Hypoalbuminemia, Severe burns, Severe liver disease.
At a glance
| Generic name | Albumin treatment |
|---|---|
| Also known as | Human Albumin Grifols 200 g/l, solution for infusion |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Albumin replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology, Nephrology |
| Phase | Phase 2 |
Mechanism of action
Albumin is a protein made by the liver that helps keep fluid in your bloodstream so it doesn't leak into other tissues. In albumin treatment, albumin is administered intravenously to patients with hypoalbuminemia, a condition characterized by low levels of albumin in the blood.
Approved indications
- Hypoalbuminemia
- Severe burns
- Severe liver disease
Common side effects
- Hypersensitivity reactions
- Anaphylaxis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albumin treatment CI brief — competitive landscape report
- Albumin treatment updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI